Analysts Set Beta Bionics, Inc. (NASDAQ:BBNX) Target Price at $23.13

Beta Bionics, Inc. (NASDAQ:BBNX) has earned a consensus rating of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat Ratings reports. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $23.13.

A number of analysts have recently commented on BBNX shares. Piper Sandler started coverage on shares of Beta Bionics in a report on Monday, February 24th. They set an “overweight” rating and a $26.00 target price on the stock. Lake Street Capital started coverage on shares of Beta Bionics in a report on Monday, February 24th. They set a “buy” rating and a $30.00 target price on the stock. Bank of America started coverage on shares of Beta Bionics in a report on Monday, February 24th. They set a “buy” rating on the stock. Leerink Partners started coverage on shares of Beta Bionics in a report on Monday, February 24th. They set an “outperform” rating and a $28.00 target price on the stock. Finally, Robert W. Baird started coverage on shares of Beta Bionics in a report on Thursday, February 20th. They set a “neutral” rating and a $20.00 target price on the stock.

Insider Transactions at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 1,497 shares of the business’s stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $17.89, for a total value of $26,781.33. Following the completion of the transaction, the chief financial officer now owns 45,503 shares of the company’s stock, valued at approximately $814,048.67. The trade was a 3.19% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 4,519 shares of company stock valued at $80,845 in the last quarter.

Hedge Funds Weigh In On Beta Bionics

Hedge funds have recently bought and sold shares of the business. Strs Ohio purchased a new position in Beta Bionics in the 1st quarter worth about $29,000. Corebridge Financial Inc. purchased a new position in Beta Bionics in the 1st quarter worth about $79,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Beta Bionics in the 1st quarter worth about $95,000. MetLife Investment Management LLC purchased a new position in Beta Bionics in the 1st quarter worth about $102,000. Finally, Deutsche Bank AG purchased a new position in Beta Bionics in the 1st quarter worth about $148,000.

Beta Bionics Trading Down 2.4%

NASDAQ:BBNX opened at $19.08 on Wednesday. The firm has a fifty day moving average of $13.05. Beta Bionics has a twelve month low of $8.89 and a twelve month high of $24.50.

Beta Bionics (NASDAQ:BBNX) last released its quarterly earnings results on Tuesday, May 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.01).

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.